Tarsier Pharma — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Latest Pulse

Jul 13, 2026Biotech's IPO Window: Open, But Only for the Strongest PipelinesTarsier Pharma's ~$45 million NYSE American debut shows biotech's IPO window remains open in 2026 -- but only for companies with genuinely differentiated, late-stage pipelines, not broad speculative interest.→

Coverage Timeline

newest first

Jul 13, 2026IPOBiotech's IPO Window: Open, But Only for the Strongest Pipelines$45M target→

All Coverage

IPO· Jul 13, 2026

Biotech's IPO Window: Open, But Only for the Strongest Pipelines

IPO$45M target

Biotech's IPO Window: Open, But Only for the Strongest Pipelines

Tarsier Pharma's ~$45 million NYSE American debut shows biotech's IPO window remains open in 2026 -- but only for companies with genuinely differentiated, late-stage pipelines, not broad speculative interest.

Jul 13, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics